HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection.

AbstractUNLABELLED:
Ebola viruses (EBOV) cause severe disease in humans and nonhuman primates with high mortality rates and continue to emerge in new geographic locations, including several countries in West Africa, the site of a large ongoing outbreak. Phosphorodiamidate morpholino oligomers (PMOs) are synthetic antisense molecules that are able to target mRNAs in a sequence-specific fashion and suppress translation through steric hindrance. We previously showed that the use of PMOs targeting a combination of VP35 and VP24 protected rhesus monkeys from lethal EBOV infection. Surprisingly, the present study revealed that a PMOplus compound targeting VP24 alone was sufficient to confer protection from lethal EBOV infection but that a PMOplus targeting VP35 alone resulted in no protection. This study further substantiates recent data demonstrating that VP24 may be a key virulence factor encoded by EBOV and suggests that VP24 is a promising target for the development of effective anti-EBOV countermeasures.
IMPORTANCE:
Several West African countries are currently being ravaged by an outbreak of Ebola virus (EBOV) that has become a major epidemic affecting not only these African countries but also Europe and the United States. A better understanding of the mechanism of virulence of EBOV is important for the development of effective treatments, as no licensed treatments or vaccines for EBOV disease are currently available. This study of phosphorodiamidate morpholino oligomers (PMOs) targeting the mRNAs of two different EBOV proteins, alone and in combination, demonstrated that targeting a single protein was effective at conferring a significant survival benefit in an EBOV lethal primate model. Future development of PMOs with efficacy against EBOV will be simplified if only one PMO is required instead of a combination, particularly in terms of regulatory approval.
AuthorsTravis K Warren, Chris A Whitehouse, Jay Wells, Lisa Welch, Alison E Heald, Jay S Charleston, Pete Sazani, St Patrick Reid, Patrick L Iversen, Sina Bavari
JournalmBio (mBio) Vol. 6 Issue 1 (Feb 10 2015) ISSN: 2150-7511 [Electronic] United States
PMID25670780 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2015 Warren et al.
Chemical References
  • Morpholinos
  • VP24 protein, Ebola virus
  • Viral Proteins
Topics
  • Animals
  • Ebolavirus (drug effects, genetics, metabolism)
  • Hemorrhagic Fever, Ebola (prevention & control, virology)
  • Humans
  • Macaca mulatta
  • Morpholinos (administration & dosage)
  • Viral Proteins (antagonists & inhibitors, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: